The Food and Drug Administration last night announced that its Vaccines and Related Biological Products Advisory Committee will convene Feb. 26 to discuss the emergency use authorization application by Johnson & Johnson and Janssen Biotech, Inc. for its investigational single-dose COVID-19 vaccine candidate.

The Johnson & Johnson candidate is the third to seek an EUA from the agency; the application follows topline efficacy and safety data culled from a phase 3 trial that showed a 72% effectiveness in the U.S. for preventing moderate-to-severe COVID-19.

Related News Articles

News
The Food and Drug Administration today revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab,…
Headline
Health care providers participating in the Centers for Disease Control and Prevention’s COVID-19 Vaccination Program must administer the vaccines at no cost to…
Headline
Drug overdose deaths in the United States rose by an estimated 29% between September 2019 and September 2020 to 90,237, according to preliminary data …
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is holding an emergency meeting this afternoon on the Johnson…
Headline
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2…
Headline
The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s…